Comments
Vaccine-maker Bharat Biotech on Saturday said a study on using Covaxin as a booster dose showed ‘promising’ results.
It announced the results from the highly anticipated trial studying the immunogenicity and safety of the Covaxin (BBV152)as a booster dose. The analysis showed, according to the Hyderabad-based vaccine maker, six months after a two-dose BBV152 vaccination, series cell-mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains persisted above baseline, although the magnitude of the responses had declined.
About 90 per cent of recipients had a detectable neutralising antibody response against the wild-type strain (6 months after the second dose).
Furthermore, neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased 19 to 265 fold after a third vaccination. Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.